Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies
Main Authors: | , , , , , , , |
---|---|
Format: | Conference item |
Published: |
Springer Verlag
2016
|
Summary: |
---|